Business Context and Reporting Period
This Form 8-K, dated March 30, 2026, reports that Aurinia Pharmaceuticals Inc. (the "Ultimate Parent") has entered into an Agreement and Plan of Merger to acquire Kezar Life Sciences, Inc. (the "Company"). The transaction involves a tender offer followed by a merger, with the closing expected in the second quarter of 2026.
Key Financial Metrics and Transaction Terms
- Offer Price: $6.955 in cash per share plus one Contingent Value Right (CVR).
- Cash Condition: Closing requires Kezar to have a minimum Closing Net Cash of $50.0 million.
- Termination Fee: Kezar may be required to pay Aurinia $1.2 million if the agreement is terminated under specific circumstances, such as accepting a superior proposal.
- Support Agreement: Tang Capital Partners, LP, holding approximately 9.0% of outstanding shares, has agreed to tender its shares.
- Financial Statements: This filing does not contain revenue, profit, cash flow, or margin data for either company.
Material Changes and Transaction Structure
The primary material change is the initiation of a definitive merger agreement. The transaction structure includes:
- Tender Offer: Aurinia Pharma U.S., Inc. must commence the offer by April 13, 2026, remaining open for 20 business days.
- Merger: Following the tender offer, a merger subsidiary will merge with Kezar, with Kezar surviving as a wholly-owned subsidiary of Aurinia.
- Equity Treatment:
- Outstanding options "in-the-money" will be cashed out based on the spread between the cash offer and exercise price, plus a CVR.
- Out-of-the-money options will be cancelled without consideration.
- Restricted Stock Units (RSUs) will vest and convert to shares prior to the effective time.
Guidance, Outlook, and Contingent Value Rights
The filing details a Contingent Value Rights (CVR) Agreement providing potential future payments to shareholders based on specific milestones and proceeds:
- Excess Cash: 100% of Closing Net Cash exceeding $50.0 million.
- Asset Proceeds: 100% of net proceeds from the Enodia Therapeutics asset purchase; 90% of net proceeds from the Everest Medicines collaboration.
- Legacy Assets (Zetomipzomib): 90% of net proceeds from the sale or license of legacy IP within two years of closing.
- Development Milestones: If Aurinia initiates a clinical study for legacy assets within two years, CVR holders may receive up to $88.0 million in milestone payments and 3% royalties on net sales over a 10-year period.
Risks and Uncertainties: The transaction is subject to customary closing conditions, including regulatory approvals and the satisfaction of the minimum cash condition. There is no assurance that CVR payments will be realized.
Investor Verification Checklist
- Verify the final Closing Net Cash of Kezar Life Sciences to ensure it meets the $50.0 million threshold.
- Review the upcoming Schedule TO (Tender Offer Statement) and Schedule 14D-9 for detailed offer terms and recommendations.
- Assess the likelihood of Aurinia initiating clinical studies for zetomipzomib within the two-year development period to realize CVR milestone value.
- Monitor the tender offer timeline, which must commence by April 13, 2026.
- Confirm the status of the 9.0% stake held by Tang Capital Partners and any other significant shareholder support.